Tue, May 13, 6:51 PM (41 days ago)
**NIKA PHARMACEUTICALS, INC. (NIKA) Q1 2025 FINANCIAL SUMMARY** **Financial Health and Performance:** - **Revenue:** $0 for Q1 2025 and Q1 2024. - **Net Loss:** $12,945 for Q1 2025, a decrease from $45,952 in Q1 2024. - **Operating Expenses:** $12,945 for Q1 2025, down from $45,952 in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $12,945 for Q1 2025, compared to $84,345 in Q1 2024. Financing activities provided $30,000 in loan proceeds from related parties. - **Liquidity:** Cash increased to $19,137 at the end of Q1 2025, up from $2,083 at the end of Q1 2024. **Key Metrics and Trends:** - **Profit Margins:** Negative due to operating losses. - **Cash Position:** Improved significantly due to related party loans. - **Operational Changes:** Significant reductions in general and administrative expenses and professional fees. **Uncertainties and Future Operations:** - **Going Concern:** Substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and lack of revenue. - **Strategic Moves:** Focus on pharmaceutical production and distribution, including mergers and acquisitions to expand market reach. - **Regulatory and Operational Risks:** Dependence on related party transactions and potential weaknesses in internal controls. **Impact on Future Operations:** - **Expansion Plans:** Continued efforts to establish a pharmaceutical factory and secure production technologies. - **Financial Strategy:** Potential need for additional capital through equity or debt financing. - **Market Position:** Aims to strengthen its foothold in Europe, Asia, and Africa through strategic partnerships and acquisitions. **Conclusion:** NIKA Pharmaceuticals, Inc. faces significant financial challenges but is actively pursuing strategic initiatives to enhance its operational capabilities and market position. The company's ability to secure additional financing and execute its business plan will be crucial for its long-term viability.